AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26392433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 23723385 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional physical therapy
Number of subjects: 188
Study 23723385 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy alone
Number of subjects: 188
Study 21700945 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril plus indapamide for eligible patients)
Number of subjects: 4283
Study 19234590 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate Milk (CM)
Number of subjects: 9
Study 19234590 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate Replacement Drink (CR)
Number of subjects: 9
Study 19234590 — intervention group
Group type: COMPARATOR
Intervention: Fluid Replacement Drink (FR)
Number of subjects: 9
Study 16605292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 947
Study 14682555 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory
Number of subjects: 0
Study 14682555 — intervention group
Group type: EXPERIMENTAL
Intervention: Wakefield Depression Inventory
Number of subjects: 0
Study 14682555 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire 28
Number of subjects: 0
Study 14682555 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedules for Clinical Assessment in Neuropsychiatry
Number of subjects: 0
Study 11813774 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based group health promotion intervention
Number of subjects: 0
Study 9212380 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical evidence present
Number of subjects: 95
Study 9212380 — intervention group
Group type: COMPARATOR
Intervention: Medical evidence absent
Number of subjects: 95
Study 9212380 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain intensity
Number of subjects: 95
Study 9212380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pain intensity
Number of subjects: 95
Study 7699376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-augmented stems (12 weeks)
Number of subjects: 60
Study 7699376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-augmented stems (6 weeks)
Number of subjects: 60
Study 7699376 — intervention group
Group type: COMPARATOR
Intervention: Nonaugmented stems (12 weeks)
Number of subjects: 60
Study 7699376 — intervention group
Group type: COMPARATOR
Intervention: Nonaugmented stems (6 weeks)
Number of subjects: 60
Study 7699376 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Charnley scoring system)
Number of subjects: 60
Study 7699376 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (plain radiographic analysis)
Number of subjects: 60
Study 7699376 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (stereographic evaluation)
Number of subjects: 60
Study 3451878 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (10 mg i.v. bolus followed by 10 mg h-1 infusion)
Number of subjects: 8
Study 3451878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30415507 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training (counseling and supervised phase for 24 weeks followed by unsupervised training for 24 weeks)
Number of subjects: 50
Study 30415507 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised training (counseling and unsupervised training for 48 weeks)
Number of subjects: 50
Study 30415507 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 50
Study 30415507 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised training
Number of subjects: 50
Study 27782950 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 Laser-assisted Sclerectomy Surgery (CLASS)
Number of subjects: 111
Study 24402830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine (1,250 mg orally QD continuously plus 20 mg/m(2)/day IV)
Number of subjects: 112
Study 24402830 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (1,250 mg orally QD continuously plus 2,000 mg/m(2)/day orally, 2 doses)
Number of subjects: 112
Study 24402830 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to lapatinib plus vinorelbine
Number of subjects: 112
Study 24402830 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to lapatinib plus capecitabine
Number of subjects: 112
Study 23452506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 161
Study 23452506 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 161
Study 20884421 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS‐CBA‐BMS
Number of subjects: 521
Study 20884421 — intervention group
Group type: COMPARATOR
Intervention: DES (Rapamycin-Eluting Stent)
Number of subjects: 521
Study 20884421 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 521
Study 18004635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB-1b)
Number of subjects: 468
Study 18004635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 16456382 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐1‐antitrypsin replacement therapy
Number of subjects: 0
Study 16456382 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography scanning
Number of subjects: 0
Study 12641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated drug-eluting stent
Number of subjects: 266
Study 12641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated drug-eluting stent (NIRx, TAXUS I trial)
Number of subjects: 266
Study 12641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated stent (RAVEL and SIRIUS trials)
Number of subjects: 266
Study 12641014 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 266
Study 9810054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion-implanted beta-titanium archwires
Number of subjects: 30
Study 9810054 — intervention group
Group type: COMPARATOR
Intervention: Unimplanted beta-titanium archwires
Number of subjects: 30
Study 7704066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot orientation program (clinic tour, general information, opportunity to ask questions)
Number of subjects: 33
Study 7704066 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 33
Study 2576115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg u.i.d.)
Number of subjects: 3
Study 2576115 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg u.i.d.)
Number of subjects: 3
Study 2576115 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 3
Study 577889 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-agent therapy (methotrexate and hydrocortisone)
Number of subjects: 91
Study 577889 — intervention group
Group type: COMPARATOR
Intervention: Three-agent therapy (methotrexate, hydrocortisone, and cytosine arabinoside)
Number of subjects: 91
Study 577889 — intervention group
Group type: COMPARATOR
Intervention: Comparison of two-agent and three-agent therapy
Number of subjects: 91
Study 7044582 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole 0.4 g (adolescents and adults) or 0.2 g (children)
Number of subjects: 186
Study 7044582 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 186
Study 31933105 — intervention group
Group type: EXPERIMENTAL
Intervention: QSAR modeling using CORAL software and Monte Carlo method for predicting antioxidant activity
Number of subjects: 111
Study 31933105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model combining hydrogen‐suppressed graph and SMILES descriptors
Number of subjects: 111
Study 31933105 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of models
Number of subjects: 111
Study 31029925 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic beet leaves and stalk juice (32 mg EAG/100 mL)
Number of subjects: 26
Study 31029925 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic beet leaves and stalk juice (77.5 mg EAG/100 mL)
Number of subjects: 26
Study 31029925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study 29322254 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal mineral water treatment for 3 weeks (15 occasions) on top of usual musculoskeletal pain killer treatment
Number of subjects: 105
Study 29322254 — intervention group
Group type: COMPARATOR
Intervention: Traditional musculoskeletal pain killer treatment
Number of subjects: 105
Study 27028128 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 1319
Study 27028128 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out plus
Number of subjects: 1319
Study 27028128 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out
Number of subjects: 1319
Study 25079040 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt with low-calorie diet (PLCD)
Number of subjects: 75
Study 25079040 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular yogurt with low-calorie diet (RLCD)
Number of subjects: 75
Study 25079040 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt without low-calorie diet (PWLCD)
Number of subjects: 75
Study 25079040 — intervention group
Group type: COMPARATOR
Intervention: Control group (Regular yogurt with low-calorie diet)
Number of subjects: 75
Study 25079040 — intervention group
Group type: COMPARATOR
Intervention: Control group (Probiotic yogurt without low-calorie diet)
Number of subjects: 75
Study 21636614 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 460
Study 21636614 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 460
Study 18436468 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with emphasis on selectively retraining the VMO (Selective)
Number of subjects: 69
Study 18436468 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with emphasis on general strengthening of the quadriceps femoris muscles (General)
Number of subjects: 69
Study 18436468 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group (Control)
Number of subjects: 69
Study 17909379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trials (CRTs)
Number of subjects: 34
Study 17909379 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for increasing acceptability of CRTs
Number of subjects: 34
Study 15546141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy alone (BT)
Number of subjects: 0
Study 15546141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy plus phone contact (BT+PC)
Number of subjects: 0
Study 15546141 — intervention group
Group type: COMPARATOR
Intervention: Phone contact alone (PC)
Number of subjects: 0
Study 11986125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11986125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 9661571 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg atracurium
Number of subjects: 30
Study 9661571 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg vecuronium
Number of subjects: 30
Study 7661384 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 33
Study 7661384 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 33
Study 7661384 — intervention group
Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 33
Study 2674875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime + amikacin (CA)
Number of subjects: 352
Study 2674875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime + pefloxacin (CP)
Number of subjects: 352
Study 2674875 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime + pefloxacin (CP) and Ceftazidime + amikacin (CA)
Number of subjects: 352
Study 1253157 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor immunotherapy
Number of subjects: 1
Study 30966802 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy
Number of subjects: 20
Study 30966802 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 20
Study 30966802 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy and IMRT
Number of subjects: 20
Study 29130724 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics therapy for eight weeks
Number of subjects: 0
Study 29130724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26083697 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational alpine skiing intervention (2-3 times per week for 12 weeks, totaling 25.5 days)
Number of subjects: 16
Study 26083697 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational alpine skiing intervention
Number of subjects: 16
Study 24351693 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 139
Study 24351693 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Angelus
Number of subjects: 139
Study 24351693 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 139
Study 21923988 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS) given every 14 days until 33+6 weeks or birth
Number of subjects: 1858
Study 19801057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation program (6-day postoperative in-hospital program including expiratory positive airway pressure mask, bronchial hygiene techniques, progressive distance walking, calisthenics, and cardiopulmonary training)
Number of subjects: 20
Study 19801057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation program
Number of subjects: 20
Study 19801057 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 16954990 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered turbinoplasty
Number of subjects: 19
Study 16954990 — intervention group
Group type: COMPARATOR
Intervention: Submucosal cauterization
Number of subjects: 19
Study 15575412 — intervention group
Group type: EXPERIMENTAL
Intervention: automatic method for registering multimodal retinal images
Number of subjects: 24
Study 12370220 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma von Willebrand factor (vWF) levels
Number of subjects: 1321
Study 12370220 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased soluble P-selectin (sP-sel) levels
Number of subjects: 1321
Study 12370220 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification based on stroke risk factors
Number of subjects: 1321
Study 9440718 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/ABV hybrid
Number of subjects: 691
Study 9440718 — intervention group
Group type: COMPARATOR
Intervention: Sequential MOPP-ABVD
Number of subjects: 691
Study 7866845 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy with cortisone injections
Number of subjects: 101
Study 7866845 — intervention group
Group type: COMPARATOR
Intervention: Standardised conventional and optimised activating treatment
Number of subjects: 101
Study 2712914 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical application of 0.4 mg prostaglandin E2 (PGE2) gel
Number of subjects: 579
Study 2712914 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin infusions
Number of subjects: 579
Study 329949 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 197
Study 329949 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 197
Study 329949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 30414164 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting biliary metal stent with sodium caprate (MSCPM-III)
Number of subjects: 106
Study 30414164 — intervention group
Group type: COMPARATOR
Intervention: Covered metal stent (CMS)
Number of subjects: 106
Study 28289033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Number of subjects: 72
Study 28289033 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of PZA (>50 mg/kg of body weight)
Number of subjects: 72
Study 28289033 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of PZA (>80 mg/kg)
Number of subjects: 72
Study 28289033 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses in the range of 30 to 40 mg/kg of PZA
Number of subjects: 72
Study 27097854 — intervention group
Group type: EXPERIMENTAL
Intervention: Copaifera langsdorffii oil resin (CLOR)
Number of subjects: 64
Study 27097854 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 64
Study 27097854 — intervention group
Group type: COMPARATOR
Intervention: White Mineral Trioxide Aggregate (WMTA)
Number of subjects: 64
Study 24366852 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair yoga
Number of subjects: 98
Study 23154555 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy
Number of subjects: 630
Study 23154555 — intervention group
Group type: COMPARATOR
Intervention: Standard inverse sequence (control)
Number of subjects: 630
Study 23154555 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line erlotinib
Number of subjects: 630
Study 23154555 — intervention group
Group type: COMPARATOR
Intervention: Wild-type patients
Number of subjects: 630
Study 19922895 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablet (ODT) 5-mg finasteride
Number of subjects: 24
Study 19922895 — intervention group
Group type: COMPARATOR
Intervention: Standard tablet 5-mg finasteride
Number of subjects: 24
Study 17966839 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lonafarnib 100 mg under fasted conditions
Number of subjects: 31
Study 17966839 — intervention group
Group type: COMPARATOR
Intervention: Single-dose lonafarnib 100 mg under fed conditions
Number of subjects: 31
Study 17966839 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose lonafarnib 200 mg Q 12 H for 28 days under fasted conditions
Number of subjects: 31
Study 17966839 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose lonafarnib 200 mg Q 12 H for 28 days under fed conditions
Number of subjects: 31
Study 14987883 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous renal tumour cell vaccine (six intradermal applications at 4-week intervals postoperatively)
Number of subjects: 379
Study 14987883 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control group)
Number of subjects: 379
Study 14987883 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous renal tumour cell vaccine
Number of subjects: 379
Study 11859938 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% perfluoropolyether phosphate (Fomblin HC/P2)
Number of subjects: 20
Study 11859938 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% perfluoropolyether phosphate (Fomblin HC/P2)
Number of subjects: 20
Study 9219134 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed wound drainage
Number of subjects: 300
Study 9219134 — intervention group
Group type: COMPARATOR
Intervention: No closed wound drainage
Number of subjects: 300
Study 8423912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine, lovastatin, nicotinic acid
Number of subjects: 25
Study 8423912 — intervention group
Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 25
Study 3610519 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine mouthwash
Number of subjects: 0
Study 3610519 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 0
Study 29389076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (20-mg capsule)
Number of subjects: 12
Study 29389076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600-mg tablet)
Number of subjects: 12
Study 29389076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene and Ibuprofen (combined)
Number of subjects: 12
Study 27365294 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate-impregnated cloths (2%) applied the night before and morning of admission
Number of subjects: 539
Study 27365294 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care antiseptic bathing (soap and water)
Number of subjects: 539
Study 24925208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and mycophenolic acid
Number of subjects: 58
Study 24925208 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine and mycophenolic acid
Number of subjects: 58
Study 24925208 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects scoring system
Number of subjects: 58
Study 22439814 — intervention group
Group type: EXPERIMENTAL
Intervention: SchoolSpace intervention involving interaction with a young person with lived experience of mental illness.
Number of subjects: 7
Study 22439814 — intervention group
Group type: EXPERIMENTAL
Intervention: SchoolSpace intervention
Number of subjects: 7
Study 20837791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection
Number of subjects: 27
Study 20837791 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 27
Study 20837791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 27
Study 18285414 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose l-T(4) (subclinical thyrotoxicosis arm)
Number of subjects: 33
Study 18285414 — intervention group
Group type: COMPARATOR
Intervention: Usual dose l-T(4) (euthyroid arm)
Number of subjects: 33
Study 15871089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl‐weighted SE sequences
Number of subjects: 45
Study 15871089 — intervention group
Group type: EXPERIMENTAL
Intervention: STIR sequences
Number of subjects: 45
Study 15871089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tl‐weighted and STIR sequences
Number of subjects: 45
Study 15871089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl‐weighted sequences for low-grade infiltration
Number of subjects: 45
Study 15871089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl‐weighted sequences for moderate infiltration
Number of subjects: 45
Study 15871089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl‐weighted sequences for high-grade infiltration
Number of subjects: 45